1
|
Kim HJ, Oh GS, Shen A, Lee SB, Khadka D, Pandit A, Shim H, Yang SH, Cho EY, Song J, Kwak TH, Choe SK, Park R, So HS. Nicotinamide adenine dinucleotide: An essential factor in preserving hearing in cisplatin-induced ototoxicity. Hear Res 2015; 326:30-9. [PMID: 25891352 DOI: 10.1016/j.heares.2015.04.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2015] [Accepted: 04/07/2015] [Indexed: 12/20/2022]
Abstract
Ototoxicity is an important issue in patients receiving cisplatin chemotherapy. Numerous studies have demonstrated that several mechanisms, including oxidative stress, DNA damage, and inflammatory responses, are closely associated with cisplatin-induced ototoxicity. Although much attention has been directed at identifying ways to protect the inner ear from cisplatin-induced damage, the precise underlying mechanisms have not yet been elucidated. The cofactor nicotinamide adenine dinucleotide (NAD(+)) has emerged as an important regulator of cellular energy metabolism and homeostasis. NAD(+) acts as a cofactor for various enzymes including sirtuins (SIRTs) and poly(ADP-ribose) polymerases (PARPs), and therefore, maintaining adequate NAD(+) levels has therapeutic benefits because of its effect on NAD(+)-dependent enzymes. Recent studies demonstrated that disturbance in intracellular NAD(+) levels is critically involved in cisplatin-induced cochlear damage associated with oxidative stress, DNA damage, and inflammatory responses. In this review, we describe the importance of NAD(+) in cisplatin-induced ototoxicity and discuss potential strategies for the prevention or treatment of cisplatin-induced ototoxicity with a particular focus on NAD(+)-dependent cellular pathways.
Collapse
Affiliation(s)
- Hyung-Jin Kim
- Center for Metabolic Function Regulation & Department of Microbiology, School of Medicine, Wonkwang University, Iksan, Jeonbuk, 570-749, Republic of Korea
| | - Gi-Su Oh
- Center for Metabolic Function Regulation & Department of Microbiology, School of Medicine, Wonkwang University, Iksan, Jeonbuk, 570-749, Republic of Korea
| | - AiHua Shen
- Center for Metabolic Function Regulation & Department of Microbiology, School of Medicine, Wonkwang University, Iksan, Jeonbuk, 570-749, Republic of Korea
| | - Su-Bin Lee
- Center for Metabolic Function Regulation & Department of Microbiology, School of Medicine, Wonkwang University, Iksan, Jeonbuk, 570-749, Republic of Korea
| | - Dipendra Khadka
- Center for Metabolic Function Regulation & Department of Microbiology, School of Medicine, Wonkwang University, Iksan, Jeonbuk, 570-749, Republic of Korea
| | - Arpana Pandit
- Center for Metabolic Function Regulation & Department of Microbiology, School of Medicine, Wonkwang University, Iksan, Jeonbuk, 570-749, Republic of Korea
| | - Hyeok Shim
- Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Jeonbuk, 570-749, Republic of Korea
| | - Sei-Hoon Yang
- Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Jeonbuk, 570-749, Republic of Korea
| | - Eun-Young Cho
- Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Jeonbuk, 570-749, Republic of Korea
| | - Jeho Song
- Department of Sports Industry and Welfare, Wonkwang University, Iksan, Jeonbuk, 570-749, Republic of Korea
| | - Tae Hwan Kwak
- PAEAN Biotechnology, 160 Techno-2 Street, Yuseong-gu, Daejeon, 305-500, Republic of Korea
| | - Seong-Kyu Choe
- Center for Metabolic Function Regulation & Department of Microbiology, School of Medicine, Wonkwang University, Iksan, Jeonbuk, 570-749, Republic of Korea
| | - Raekil Park
- Center for Metabolic Function Regulation & Department of Microbiology, School of Medicine, Wonkwang University, Iksan, Jeonbuk, 570-749, Republic of Korea
| | - Hong-Seob So
- Center for Metabolic Function Regulation & Department of Microbiology, School of Medicine, Wonkwang University, Iksan, Jeonbuk, 570-749, Republic of Korea.
| |
Collapse
|
2
|
Uemura M, Suzuki T, Nishio K, Chikuma M, Komeda S. An in vivo highly antitumor-active tetrazolato-bridged dinuclear platinum(ii) complex largely circumvents in vitro cisplatin resistance: two linkage isomers yield the same product upon reaction with 9-ethylguanine but exhibit different cytotoxic profiles. Metallomics 2012; 4:686-92. [DOI: 10.1039/c2mt20026k] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
4
|
Abstract
Two major classes of drugs currently in clinical use can cause permanent hearing loss. Aminoglycoside antibiotics have a major role in the treatment of life-threatening infections and platinum-based chemotherapeutic agents are highly effective in the treatment of malignant disease. Both damage the hair cells of the inner ear, resulting in functional deficits. The mechanisms underlying these troublesome side effects are thought to involve the production of reactive oxygen species in the cochlea, which can trigger cell-death pathways. One strategy to protect the inner ear from ototoxicity is the administration of antioxidant drugs to provide upstream protection and block the activation of cell-death sequences. Downstream prevention involves the interruption of the cell-death cascade that has already been activated, to prevent apoptosis. Challenges and opportunities exist for appropriate drug delivery to the inner ear and for avoiding interference with the therapeutic efficacy of both categories of ototoxic drugs.
Collapse
Affiliation(s)
- Leonard P Rybak
- Department of Surgery, Southern Illinois University, School of Medicine, P.O. Box 19653, Springfield, IL 62794-9653, USA.
| | | |
Collapse
|